Master D-dimer testing in pulmonary embolism with age-adjusted cutoffs, assay comparisons, probability-adapted thresholds, and integration with clinical prediction rules for emergency physicians, radiologists, and laboratory medicine specialists.

D-Dimer Pulmonary Embolism: The Complete Evidence-Based Diagnostic Guide for 2026

1. Introduction to D-dimer in PE diagnosis

D-dimer testing has transformed the diagnostic approach to suspected pulmonary embolism, enabling safe exclusion of venous thromboembolism without imaging in approximately 30-50% of patients presenting to emergency departments. As a degradation product of cross-linked fibrin, D-dimer reflects ongoing fibrinolysis and serves as a highly sensitive—but poorly specific—marker of thrombotic activation.

The 2026 AHA/ACC multidisciplinary guideline and the 2019 ESC/ERS guidelines both reaffirm D-dimer as a cornerstone of PE diagnostic pathways, but emphasise that it must be applied selectively within validated clinical algorithms. Used indiscriminately, D-dimer generates false-positive results in infection, malignancy, pregnancy, trauma, surgery, and advanced age, driving unnecessary CT pulmonary angiography (CTPA) examinations with attendant radiation exposure, contrast load, and healthcare costs.

2. Pathophysiology and assay principles

2a. Fibrin formation and degradation

During coagulation activation, thrombin cleaves fibrinogen to form fibrin monomers, which polymerise into soluble fibrin strands. Factor XIIIa cross-links these strands to form stable fibrin clots. The fibrinolytic system then degrades cross-linked fibrin via plasmin, generating a heterogeneous mixture of degradation products. D-dimer is the smallest terminal degradation product containing the cross-linked D-domain, making it specific for fibrin (rather than fibrinogen) degradation.

2b. D-dimer assay methodologies

D-dimer is not a standardized analyte; there is no international reference material, and assays detect different epitopes on fibrin degradation products. This heterogeneity means results are not interchangeable between methods.

Assay type	Method	Typical cutoff	Characteristics
Latex agglutination	Semi-quantitative visual assessment	Variable	Point-of-care; rapid; lower sensitivity
Enzyme-linked fluorescent (ELFA)	VIDAS DD Exclusion	500 μg/L	High sensitivity; widely validated
Latex-enhanced immunoturbidimetric	Innovance, Tina-quant	500 μg/L	High throughput; assay-specific performance
Immunochromatographic	LumiraDx point-of-care	500 μg/L	Bedside testing; 5-minute turnaround
Immunoassay	STA Liatest	500 μg/L	Variable specificity across platforms

The ideal D-dimer assay for PE exclusion combines high clinical sensitivity (>95%) with acceptable specificity. Because D-dimer is used primarily to rule out disease in low-probability patients, sensitivity is the paramount performance characteristic.

3. Standard D-dimer cutoff and limitations

The conventional D-dimer cutoff of 500 μg/L fibrinogen equivalent units (FEU) has been validated across numerous prospective cohorts. In patients with low or intermediate pretest probability, a D-dimer below this threshold safely excludes PE with a negative likelihood ratio approaching 0.10 and a 3-month thromboembolic risk below 1.0%.

However, the standard cutoff suffers from a critical limitation: specificity decreases dramatically with advancing age. In patients over 80 years, specificity may fall below 10%, meaning more than 90% of elderly patients without PE will have a positive D-dimer. This drives substantial overuse of CTPA in populations where radiation and contrast risks are most consequential.

4. Age-adjusted D-dimer cutoffs

4a. The ADJUST-PE study

The landmark ADJUST-PE study (2014) established the safety of age-adjusted D-dimer (AADD) in outpatients with suspected PE. The formula is elegantly simple:

In the original ADJUST-PE prospective cohort of 3,319 patients, AADD increased the proportion of patients in whom PE could be excluded from 6.4% to 29.7% in patients over 75 years, with a failure rate (venous thromboembolism during 3-month follow-up) of only 0.3%.

4b. Validation and meta-analyses

Multiple subsequent meta-analyses have confirmed the safety of AADD. A 2021 systematic review of 13,000 patients demonstrated that AADD maintained sensitivity above 97% while increasing specificity by absolute margins of 12-24% across age groups over 50. The 2026 AHA/ACC guideline now endorses age-adjusted D-dimer as a Class IIa recommendation for patients over 50 years with low or intermediate pretest probability.

4c. Probability-adapted cutoffs: The YEARS algorithm

The YEARS algorithm takes D-dimer refinement further by combining clinical pretest probability with probability-adapted D-dimer thresholds:

Clinical criteria	Points
Clinical signs of DVT	1
Haemoptysis	1
PE most likely diagnosis	1

Interpretation:

• 0 points + D-dimer <1000 ng/mL: PE excluded (no imaging)
• ≥1 point + D-dimer <500 ng/mL: PE excluded (no imaging)
• All other combinations: Proceed to CTPA

The YEARS algorithm safely reduces CTPA utilisation by approximately 14% compared to standard D-dimer testing with Wells score, without increasing missed PE diagnoses.

5. Probability-adapted and clinical prediction rules

5a. Wells score integration

The simplified Wells score categorises patients as PE likely (>4 points) or PE unlikely (≤4 points). D-dimer testing is reserved for the “unlikely” group; the “likely” group proceeds directly to CTPA.

Variable	Points
Clinical signs of DVT	3
PE #1 diagnosis OR equally likely	3
Heart rate >100 bpm	1.5
Immobilisation or surgery in prior 4 weeks	1.5
Previous DVT/PE	1.5
Haemoptysis	1
Malignancy (treatment within 6 months)	1

5b. Revised Geneva score

The revised Geneva score is entirely clinical (no subjective physician judgement) and performs similarly to Wells:

Variable	Points
Age >65 years	1
Previous DVT/PE	3
Surgery or fracture within 1 month	2
Active malignancy	2
Unilateral lower limb pain	3
Haemoptysis	2
Heart rate 75-94 bpm	3
Heart rate ≥95 bpm	5
Pain on lower limb palpation and unilateral oedema	4

Score 0-3: low probability (proceed to D-dimer). Score 4-10: intermediate probability (proceed to D-dimer). Score ≥11: high probability (proceed to CTPA).

5c. PERC rule

The Pulmonary Embolism Rule-out Criteria (PERC) can be applied to low-risk patients to avoid both D-dimer testing and imaging. A patient must satisfy all eight criteria:

1. Age <50 years
2. Heart rate <100 bpm
3. Oxygen saturation ≥95%
4. No unilateral leg swelling
5. No haemoptysis
6. No recent surgery or trauma (within 4 weeks)
7. No prior venous thromboembolism
8. No hormone use (oral contraceptives, oestrogen therapy)

PERC-negative patients have a 3-month thromboembolic risk below 1.0% without any further testing.

6. D-dimer assay comparison

A 2025 secondary analysis of the ADJUST-PE study compared five D-dimer assays using age-adjusted cutoffs:

Assay	Failure rate (<2% target)	Safety vs VIDAS
VIDAS DD Exclusion (reference)	<2%	Reference standard
Innovance DD	<2%	Equivalent safety
LumiraDx (point-of-care)	<2%	Equivalent safety
STA Liatest	<2%	Higher false-negative rate; 3 missed PE
Tina-quant DD	<2%	Higher false-negative rate; 5 missed PE

This analysis demonstrates that not all D-dimer assays perform equivalently when age-adjusted cutoffs are applied. Laboratories implementing AADD should validate their specific assay against clinical outcomes or compare performance with established high-sensitivity methods.

7. Integrated clinical algorithms

7a. Standard algorithm (Wells + D-dimer)

1. Calculate simplified Wells score
2. If PE likely (>4 points): proceed to CTPA
3. If PE unlikely (≤4 points): obtain D-dimer
4. If D-dimer <500 μg/L: PE excluded; consider alternative diagnosis
5. If D-dimer ≥500 μg/L: proceed to CTPA

7b. Age-adjusted algorithm (ADJUST-PE)

1. Calculate simplified Wells score
2. If PE likely: proceed to CTPA
3. If PE unlikely: obtain D-dimer
4. If age ≤50 years and D-dimer <500 μg/L: PE excluded
5. If age >50 years and D-dimer <(age × 10) μg/L: PE excluded
6. If D-dimer above threshold: proceed to CTPA

7c. YEARS algorithm

1. Assess YEARS clinical criteria
2. If 0 points and D-dimer <1000 ng/mL: PE excluded
3. If ≥1 point and D-dimer <500 ng/mL: PE excluded
4. All others: proceed to CTPA

8. Special populations and confounders

8a. Pregnancy

Pregnancy increases D-dimer concentration progressively through gestation, rendering the standard 500 μg/L cutoff virtually useless in the third trimester. Trimester-specific reference ranges have been proposed but lack prospective validation for PE exclusion. The 2019 ESC guidelines recommend CTPA as the first-line imaging test in pregnant patients with high clinical suspicion, bypassing D-dimer in many cases.

8b. Cancer

Malignancy elevates D-dimer through chronic thrombin generation and fibrin turnover. The specificity of D-dimer in cancer patients is approximately 15-25%. Clinical prediction rules still apply, but physicians should maintain a lower threshold for proceeding to imaging when cancer is active or recently treated.

8c. Infection and inflammation

Sepsis, pneumonia, and severe inflammatory states markedly elevate D-dimer through endothelial activation and microvascular thrombosis. In patients hospitalised with COVID-19, D-dimer levels correlate with disease severity and thrombotic risk, but should not be used alone to exclude PE in symptomatic patients.

8d. Recent surgery and trauma

Postoperative D-dimer elevation is universal after major surgery. The optimal timing for D-dimer testing in postoperative patients with suspected PE remains uncertain; many experts recommend proceeding directly to CTPA if clinical suspicion is moderate or high.

8e. Elderly patients

This is precisely where age-adjusted D-dimer demonstrates its greatest utility. Without AADD, approximately 60-70% of patients over 80 years have positive D-dimer results. AADD reduces this to 30-40%, safely excluding PE in a substantial proportion of elderly low-risk patients.

9. Diagnostic pitfalls and false results

Scenario	Mechanism	Clinical approach
False-negative D-dimer	Early presentation (<4 hours); small distal PE; low fibrin burden	If high clinical suspicion, do not exclude PE based on D-dimer alone; obtain CTPA
False-positive D-dimer	Age >50; infection; malignancy; pregnancy; trauma; surgery	Use age-adjusted or probability-adapted cutoffs; apply clinical prediction rules
Delayed PE presentation	D-dimer may normalise after 7-14 days	Do not use D-dimer to exclude PE in patients with symptoms >2 weeks
Subsegmental PE	Small clot burden may not generate sufficient fibrin degradation	D-dimer sensitivity is lower for subsegmental PE; imaging may be required
Anticoagulation effect	Therapeutic anticoagulation reduces fibrin formation and D-dimer generation	D-dimer is unreliable for PE exclusion in patients already anticoagulated

10. Further reading

1. 7 Critical CT Pulmonary Angiogram Protocol Steps — Complete CTPA technique guide for when D-dimer is positive and imaging is indicated.
2. 7 Essential Contrast Chest CT Protocol Steps Radiographers Must Master — Foundational contrast-enhanced thoracic CT technique complementary to emergency PE imaging.
3. CT & MRI Contrast Media Calculator — Weight-based contrast dosing tool for CTPA following positive D-dimer results.
4. 7 Essential High-Pressure Injector Training Skills for Radiographers — Critical injector training for rapid CTPA deployment after D-dimer positivity.
5. SATLine High-Pressure Consumables — Dual-valve patient lines ensuring reliable contrast delivery during emergency CTPA protocols.
6. SATPro Radiation Protection — Disposable sterile scatter reduction drapes for high-volume emergency CT suites.

11. Conclusion

D-dimer testing remains an indispensable tool in the diagnostic evaluation of suspected pulmonary embolism, but its value depends entirely on appropriate patient selection, validated cutoff application, and integration with clinical prediction rules. The standard 500 μg/L cutoff, while safe, is excessively conservative for older populations and generates unnecessary imaging in patients where radiation and contrast risks are most significant.

Age-adjusted D-dimer, using the simple formula of age × 10 μg/L for patients over 50 years, safely increases specificity without compromising the near-perfect negative predictive value required for thromboembolism exclusion. The YEARS algorithm further refines this approach through probability-adapted thresholds, reducing CTPA utilisation while maintaining diagnostic safety.

Laboratories and clinicians must recognise that D-dimer assays are not interchangeable. Assay-specific validation is essential before implementing adjusted cutoffs. Furthermore, D-dimer should never be interpreted in isolation; it must always be embedded within structured clinical algorithms that account for pretest probability, special populations, and confounding conditions.

For radiologists and radiographers, understanding the strengths and limitations of D-dimer informs appropriate imaging triage, reduces unnecessary CTPA examinations, and ensures that when imaging is indicated, it is performed with optimal protocol parameters and patient safety considerations.

12. References

1. 1 Righini, M., Van Es, J., Den Exter, P. L., Roy, P. M., Verschuren, F., Ghuysen, A., Rutschmann, O. T., Sanchez, O., Jaffrelot, M., Trinh-Duc, A., Le Gall, C., Moustafa, F., Principe, A., Van Houten, A. A., Ten Wolde, M., Douma, R. A., Hazelaar, G., Akkerhuis, K. M., Bresser, P., … Klok, F. A. (2014). Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA, 311(11), 1117-1124. https://doi.org/10.1001/jama.2014.2135
2. 2 Robert-Ebadi, H., et al. (2025). Different D-dimer assays with age-adjusted cutoffs to exclude pulmonary embolism: Secondary analysis of ADJUST-PE study. Journal of Thrombosis and Haemostasis, 23(4), 891-899. https://doi.org/10.1016/j.jtha.2024.12.015
3. 3 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. (2026). Circulation. https://doi.org/10.1161/CIR.0000000000001415
4. 4 Konstantinides, S. V., & Meyer, G. (2019). 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal, 41(4), 543-603. https://doi.org/10.1093/eurheartj/ehz405
5. 5 van der Hulle, T., Cheung, W. Y., Kooij, S., Beenen, L. F., van Bemmel, T., van Es, J., … Klok, F. A. (2017). Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): A prospective, multicentre, cohort study. The Lancet, 390(10091), 289-297. https://doi.org/10.1016/S0140-6736(17)30885-1
6. 6 Wells, P. S., Anderson, D. R., Rodger, M., Stiell, I., Dreyer, J. F., Barnes, D., Forgie, M., Kovacs, G., Ward, J., & Kovacs, M. J. (2001). Excluding pulmonary embolism at the bedside without diagnostic imaging: Management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Annals of Internal Medicine, 135(2), 98-107. https://doi.org/10.7326/0003-4819-135-2-200107170-00010
7. 7 Kline, J. A., Mitchell, A. M., Kabrhel, C., Richman, P. B., & Courtney, D. M. (2004). Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. Journal of Thrombosis and Haemostasis, 2(8), 1247-1255. https://doi.org/10.1111/j.1538-7836.2004.00790.x
8. 8 Le Gal, G., Righini, M., Roy, P. M., Sanchez, O., Aujesky, D., Bounameaux, H., & Perrier, A. (2006). Prediction of pulmonary embolism in the emergency department: The revised Geneva score. Annals of Internal Medicine, 144(3), 165-171. https://doi.org/10.7326/0003-4819-144-3-200602070-00004
9. 9 Di Nisio, M., Squizzato, A., Rutjes, A. W., Büller, H. R., Zwinderman, A. H., & Bossuyt, P. M. (2007). Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: A systematic review. Journal of Thrombosis and Haemostasis, 5(2), 296-304. https://doi.org/10.1111/j.1538-7836.2007.02336.x
10. 10 Stein, P. D., Hull, R. D., Patel, K. C., Olson, R. E., Alshabani, A., Ghali, W. A., Brant, R., Biel, R. K., Kalra, N. K., & Karalius, V. (2004). D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: A systematic review. Annals of Internal Medicine, 140(8), 589-602. https://doi.org/10.7326/0003-4819-140-8-200404200-00004
11. 11 Schrecengost, J. E., LeGallo, R. D., Boyd, J. C., Moons, K. G., Gonias, S. L., & Rose, C. E. (2003). Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism. Clinical Chemistry, 49(8), 1483-1485. https://doi.org/10.1373/49.8.1483
12. 12 Carrier, M., Righini, M., Djurabi, R. K., Huisman, M. V., Perrier, A., Wells, P. S., Rodger, M., Wuillemin, W. A., & Le Gal, G. (2009). VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism: A systematic review of management outcome studies. Thrombosis and Haemostasis, 101(5), 886-892. https://doi.org/10.1160/TH-08-10-0689
13. 13 Penaloza, A., Roy, P. M., Kline, J., Verschuren, F., Gourcy, V., & Derlon, V. (2012). Performance of age-adjusted D-dimer cutoff to rule out pulmonary embolism. Journal of Thrombosis and Haemostasis, 10(7), 1291-1296. https://doi.org/10.1111/j.1538-7836.2012.04769.x
14. 14 Sharif, S., Eventov, M., Kearon, C., Parpia, S., Li, M., Jiang, I., Snow, G., & de Wit, K. (2021). Age-adjusted D-dimer to rule out pulmonary embolism: A systematic review and meta-analysis. Canadian Journal of Emergency Medicine, 23(4), 517-526. https://doi.org/10.1007/s43678-021-00155-7
15. 15 Freund, Y., Cachanado, M., Aubry, A., Orini, S., Fermann, G., Giraudeau, B., Ray, P., Riou, B., & Douillet, J. (2018). Effect of the pulmonary embolism rule-out criteria on subsequent thromboembolic events among low-risk emergency department patients: The PROPER randomized clinical trial. JAMA, 319(6), 559-566. https://doi.org/10.1001/jama.2017.21904
16. 16 Hugli, O., Righini, M., Le Gal, G., Howarth, N., & Bounameaux, H. (2010). The pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary embolism. Journal of Thrombosis and Haemostasis, 8(5), 951-957. https://doi.org/10.1111/j.1538-7836.2010.03807.x
17. 17 Goodacre, S., Sampson, F., Thomas, S., van Beek, E., & Sutton, A. (2005). Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Medical Imaging, 5(1), 6. https://doi.org/10.1186/1471-2342-5-6
18. 18 Stein, P. D., Fowler, S. E., Goodman, L. R., Gottschalk, A., Hales, C. A., Hull, R. D., Leeper, K. V., Popovich, J., Quinn, D. A., Sos, T. A., Sostman, H. D., Tapson, V. F., Wakefield, T. W., Weg, J. G., & Woodard, P. K. (2006). Multidetector computed tomography for acute pulmonary embolism. New England Journal of Medicine, 354(22), 2317-2327. https://doi.org/10.1056/NEJMoa052367
19. 19 Leung, A. N., Bull, T. M., Jaeschke, R., Lockwood, C. J., Boiselle, P. M., Hurwitz, L. M., James, A. H., McCullough, L. B., Menda, Y., Paidas, M. J., Royal, H. D., Tapson, V. F., Winer-Muram, H. T., Chervenak, F. A., & Cody, D. D. (2011). An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: Evaluation of suspected pulmonary embolism in pregnancy. American Journal of Respiratory and Critical Care Medicine, 184(10), 1200-1208. https://doi.org/10.1164/rccm.201108-1575ST
20. 20 van Mens, T. E., Scheres, L. J., de Jong, P. G., Leeflang, M. M., Büller, H. R., & Middeldorp, S. (2017). Imaging for the exclusion of pulmonary embolism in pregnancy. Cochrane Database of Systematic Reviews, 1(1), CD011053. https://doi.org/10.1002/14651858.CD011053.pub2
21. 21 Di Nisio, M., van Es, N., & Büller, H. R. (2016). Deep vein thrombosis and pulmonary embolism. The Lancet, 388(10063), 3060-3073. https://doi.org/10.1016/S0140-6736(16)30514-1
22. 22 Reassessing D-dimer Cut-offs for Pulmonary Embolism. (2024). Cureus, 16(3), e55214. https://doi.org/10.7759/cureus.55214
23. 23 Silveira, P. C., Ip, I. K., Goldsmith, A. J., & Khorasani, R. (2015). Pregnancy, D-dimer, and computed tomography pulmonary angiography: A review. Journal of Thrombosis and Thrombolysis, 39(1), 51-57. https://doi.org/10.1007/s11239-014-1137-0
24. 24 Schouten, H. J., Geersing, G. J., Koek, H. L., Zuithoff, N. P., Janssen, K. J., Douma, R. A., van Delden, J. J., Moons, K. G., & Reitsma, J. B. (2013). Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: Systematic review and meta-analysis. BMJ, 346, f2492. https://doi.org/10.1136/bmj.f2492
25. 25 Raja, A. S., Greenberg, J. O., Qaseem, A., Denberg, T. D., Fitterman, N., Lipscomb, P. A., Schuur, J. D., & Weinberger, S. E. (2015). Evaluation of patients with suspected acute pulmonary embolism: Best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Annals of Internal Medicine, 163(9), 701-711. https://doi.org/10.7326/M14-1772
26. 26 Kearon, C., de Wit, K., Parpia, S., Schulman, S., Afilalo, M., Hirsch, A., Spencer, F. A., Sharma, S., & D’Aragon, F. (2019). Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. New England Journal of Medicine, 381(22), 2125-2134. https://doi.org/10.1056/NEJMoa1909159